Recombinant CD25 antibody

Catalog No. ABIN7543078

This anti-CD25 antibody is a Mouse Monoclonal antibody detecting CD25 in FACS, ELISA, IP and IF. Suitable for Human.

Quick Overview for Recombinant CD25 antibody (ABIN7543078)

Target: CD25 (IL2RA) (Interleukin 2 Receptor, alpha (IL2RA))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD25 antibody is un-conjugated

Application: Flow Cytometry (FACS), ELISA, Immunoprecipitation (IP), Immunofluorescence (IF)

Clone: 7G7-B6

Product Details anti-CD25 Antibody

Purpose: Anti-CD25 [7G7/B6], Mouse IgG2a, kappa

Specificity: This antibody is specific for human interleukin 2 (IL2) receptor alpha (IL2RA), which is expressed by activated T cells. IL2R alpha chains can exist as low-affinity monomers, or can non-covalently associate with IL2R beta chains to form high-affinity dimers.

Characteristics:

Original Species of Ab: Mouse

Original Format of Ab: IgG2a

Purification: Protein A affinity purified

Immunogen: This antibody was raised by injecting mice intraperitoneally and subcutaneously with Hong Kong influenza virus-stimulated PBMC, which express human IL-2 receptor alpha. Immune splenocytes were subsequently fused with SP2/0 cells to produce stable hybridomas.

Isotype: IgG2a kappa

Application Details

Application Notes: This antibody recognises human IL2RA, as confirmed by immunofluorescence, FACS and immunoprecipitation analysis (Rubin et al, 1985). Sequential immunoprecipitations have shown that 7G7/B6 binds to the same 50-55 kD surface molecule as anti-Tac, a murine mAb specific for the human IL-2 receptor. However, 7G7/B6 does not compete with IL-2 and anti-Tac for binding to IL2R expressed by activated PBMCs, indicating that 7G7/B6 recognises a distinct epitope on IL2R. 7G7/B6, therefore, recognises a different epitope on IL-2Rα to the humanised anti-Tac monoclonal antibody daclizumab (Zhang et al, 2006). Equally, although 7G7/B6 binds to a different epitope on IL2 Rα to IL-2, and is, therefore, unable to block IL-2/IL2 Rα interaction, 7G7/B6 is still able to delay tumour progression and prolong survival in mouse models of adult T-cell leukaemia (ATL) (Phillips et al, 2000), likely by FcR-mediated death by FcRIII-expressing cells. Administration of 7B7/B6 radiolabelled with astatine-211 (211At-7G7/B6) to karpas299 leukaemia-bearing mice significantly increased survival, highlighting the potential therapeutic role for 211At-7G7/B6 in the treatment of patients with CD25-expressing leukaemias (Zhang et al, 2006). Indeed, 211At-7G7/B6 in combination with daclizumab induces significant long-term survival in murine models of adult T-cell leukaemia (Zhang et al, 2006). Additionally, 7G7/B6 armed with Yttrium-90 (90Y) significantly extends the survival of SUDHL-1 lymphoma-bearing mice significantly (Zhang et al, 2009), and presents another option for combination therapy with daclizumab. 7G7/B6 has been used in flow cytometric measurements of energy transfer efficiencies between FITC- and Cy3-conjugated mAbs bound to IL-2Rα, β, and γ subunits on Kit 225 K6 T cells, revealing that IL-2R subunits are preassembled on resting cells (Damjanovich et al, 1997). This antibody has also been used in an ELISA to assess serum levels of IL-2R (Uziel et al, 1994).

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for CD25

Target: CD25 (IL2RA) (Interleukin 2 Receptor, alpha (IL2RA))

Alternative Name: CD25

Background: IL2-RA, Interleukin-2 receptor subunit alpha, IL-2-RA, IL-2R subunit alpha, TAC antigen, p55, Receptor for interleukin-2

UniProt: P01589

Pathways: JAK-STAT Signaling, Growth Factor Binding, Activated T Cell Proliferation